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AbstrAct
The diagnosis of sporadic Creutzfeldt-Jakob 
disease (CJD) can be difficult, but the real-time 
quaking-induced conversion (RT-QuIC) assays 
have made a considerable impact on its clinical 
diagnosis. This technique exploits the ability 
of the misfolded pathological form of prion 
protein (PrPSc) found in cerebrospinal fluid 
(CSF) to induce conversion of normal PrP to the 
misfolded form, which subsequently aggregates. 
The formation of these aggregates of misfolded 
PrP is monitored in real time using fluorescent 
dyes. The current sensitivity of CSF RT-QuIC 
undertaken at the UK National CJD Research 
& Surveillance Unit is 92% and the specificity 
is 100%. The interpretation of the RT-QuIC 
traces is affected by the presence of raised 
CSF red and white cells counts and elevated 
total protein concentrations. We recommend 
that CSF samples for RT-QuIC analysis are clear 
and colourless with a white cell count of  <10 
x10^6/L and have a total protein concentration 
of <1 g/L.
IntroductIon
Creutzfeldt-Jakob disease (CJD) is a fatal 
neurodegenerative disease belonging to 
a family of diseases known as transmis-
sible spongiform encephalopathies, which 
affect both humans and farmed and wild 
animals. These diseases are associated 
with the deposition within the brain of an 
abnormally folded and protease-resistant 
form (PrPSc) of cellular protein known 
as prion protein (PrPC). PrPSc is able to 
bind to PrPC to induce misfolding and the 
creation of additional PrPSc, which can 
then induce further PrPC misfolding and 
subsequent aggregation into fibrils and 
plaques. Thus small amounts of PrPSc are 
able to propagate throughout the central 
nervous system.
CJD is the most common form of trans-
missible spongiform encephalopathy in 
humans; 85% of cases are sporadic in 
nature, with most of the remaining cases 
being genetic in origin (15%), secondary 
to mutations in the prion protein gene 
(PRNP). A very small number of cases are 
iatrogenic in nature due to the administra-
tion of human cadaveric growth hormone 
in the 1970–1980s or the use of affected 
dura mater grafts. Variant CJD, acquired 
through ingesting foodstuffs contam-
inated by bovine spongiform enceph-
alopathy or related to transfusion of 
contaminated blood or blood products, is 
increasingly rare.1
Sporadic CJD is associated with a 
rapidly progressing dementia and neuro-
logical features such as ataxia and myoc-
lonus; death usually occurs within 6 
months. The diagnosis can be difficult in 
the early stages and is made on the pres-
ence of a series of clinical features and 
distinctive abnormalities in supportive 
investigations, such as triphasic waves on 
electroencephalogram, high signal in the 
basal ganglia on MR scan of the brain, 
and the detection of cerebrospinal fluid 
(CSF) 14-3-3 and other markers of acute 
neuronal damage such as tau protein 
in CSF.2 3 All these investigations are 
hampered by the fact that they are surro-
gate markers and as such detect changes 
that can occur in many other conditions. 
Therefore, none of these investigations 
are specific for CJD and none can detect 
all sporadic CJD (sCJD) subtypes.4 5
reAl-tIme quAkIng-Induced 
conversIon
The characteristic neuropathological hall-
mark of transmissible spongiform enceph-
alopathies is the presence of PrPSc. There 
have been many different approaches to 
try to detect PrPSc; however, these have 
been hampered by the very small amounts 
present in body fluids such as CSF and 
blood, but also by the lack of antibodies 
that can distinguish PrPSc from PrPC.
Real-time quaking-induced conver-
sion (RT-QuIC) was described in 2010, 
a new technique to detect small amounts 
of PrPSc.6 7 This technique exploits the 
ability of PrPSc to induce PrPC to misfold 
in a cyclical fashion to form aggregates 
of PrPSc fibrils. The formation of these 
aggregates is monitored in real time by 
their ability to bind a fluorescent dye, 
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Figure 1 Real-time quaking-induced conversion reactions seeded with sporadic Creutzfeldt-Jakob disease brain homogenate 
as positive control (red), Alzheimer’s disease brain homogenate (yellow), sudden death brain homogenate from subject with no 
neuropathological abnormality (green) and unseeded reaction (blue) as negative controls. ThT, thioflavin T.
namely thioflavin T (figure 1). In brief, CSF from a 
patient suspected of having CJD is added to a mixture 
of recombinant PrP (rPrP) and thioflavin T. Any PrPSc 
present in the CSF binds to the rPrP and induces it to 
change shape and form fibrils. This process can take up 
to 30 hours and is known as the lag phase, after which 
time the fibrils start to aggregate and bind thioflavin T, 
which starts to fluoresce (figure 2). This fluorescence 
is monitored in real time. The aggregation kinetics are 
monitored and show a characteristic sigmoidal curve. 
The first studies used either full-length hamster rPrP 
(23-231) or full-length human rPrP and reported sensi-
tivities between 69% and 89% for neuropathologically 
confirmed sCJD, and specificities between 99% and 
100% (table 1).6 8–13
In addition to using different forms of rPrP, these 
studies also used different instrumentation and slight vari-
ations in methods. To ensure that there was concordance 
among these different techniques, we undertook a quality 
assurance assessment. Two sets of identical CSF samples, 
containing CSF samples from patients with either sCJD 
or another neurodegenerative condition, were sent to 10 
laboratories undertaking RT-QuIC analysis and analysed 
blind to the final diagnosis. There was very good concor-
dance with the first set of samples and complete concor-
dance with the second.14 Therefore, there is a good 
agreement between laboratories undertaking RT-QuIC 
analysis worldwide.
Despite the name, RT-QuIC is actually a long process 
taking 90 hours to reach completion. There is now an 
adaptation of RT-QuIC known as either improved 
RT-QuIC (IQ) or second-generation RT-QuIC using 
truncated hamster rPrP (90-231) as substrate. This 
has the same order of sensitivity (70%–96%) as the 
traditional RT-QuIC but a much shorter analytical 
time of approximately 30 hours.11 13 15–17 The speci-
ficity of this substrate is 98%–100% (table 1). There is 
currently a worldwide comparative study of both the 
first-generation and second-generation RT-QuIC tech-
niques under way.
A direct comparison of RT-QuIC with CSF 14-3-3 
and tau protein has shown that RT-QuIC has greater 
sensitivity and specificity than either CSF 14-3-3 or 
tau protein.8 12 16 18
clInIcAl And AnAlytIcAl FActors AFFectIng 
rt-quIc AFFectIng perFormAnce
sporadic cJd subtypes
Sporadic CJD is a heterogeneous disease with six clin-
icopathological subtypes based on the PRNP codon 
129 genotype: homozygous for methionine (MM) 
or valine (VV) and heterozygous for methionine and 
valine (MV), and the type of PrPSc accumulating within 
the brain (type 1 or 2). Most sCJD cases are MM1, 
MV1, MV2 or VV2, with MM2 and VV1 cases rarer.19 
The sensitivity of CSF RT-QuIC is not influenced by 
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Figure 2 Real-time quaking-induced conversion reactions seeded with cerebrospinal fluid from a patient with sporadic Creutzfeldt-
Jakob disease (sCJD) (red) and a patient without sCJD or related prion disorder (blue). ThT, thioflavin T.
PRNP codon 129 alone (table 1), but CSF RT-QuIC 
does appear to have a lower sensitivity in patients with 
sCJD-MM2 and sCJD-VV1 (table 2). We do not know 
the significance of this at present as there are only 
small numbers of cases involved, but its significance 
may become clearer with more cases analysed.
Age at onset of disease, disease duration and timing of 
lumbar puncture
The detection of CSF 14-3-3 is influenced by the age 
at disease onset, disease duration and timing of lumbar 
puncture, with the highest sensitivity in patients with 
shortest disease duration, older than 40 years old 
and in the later stages of disease.20 21 It is less clear 
whether these factors influence CSF RT-QuIC posi-
tivity. McGuire et al8 reported no influence of age at 
onset of disease, stage of disease or disease duration; 
however, Cramm et al22 noted that patients with a 
shorter disease duration had higher seeding activity 
as measured by a shorter lag phase and higher final 
fluorescence values. Clearly this needs further investi-
gation, and studies are under way to examine the rela-
tionship between CSF RT-QuIC and disease duration 
or severity at time of CSF collection.
Analytical factors
CSF RT-QuIC is not affected by storage of CSF 
samples at room temperature or 4°C for up to 8 days 
nor is it affected by repeated freeze–thaw cycles.23 
However, blood contamination in CSF samples does 
affect RT-QuIC. Red cells in CSF samples inhibit the 
RT-QuIC response, with fewer replicates giving a 
positive response, longer reaction times and reduced 
final responses.16 23 A cut-off of <1250 x 10^6/L has 
been recommended.23 The haem moiety in haemo-
globin is probably responsible for quenching the fluo-
rescent signal, and thereby reducing the RT-QuIC 
response.
We have also found that high CSF total protein 
concentrations of >1.0 g/L and raised white cell 
counts (WCC) may result in an RT-QuIC response 
that shows a high and fluctuating baseline that could 
be misinterpreted as a positive RT-QuIC response. As 
a result, we must interpret CSF RT-QuIC with caution 
in those samples with elevated total protein or WCC. 
Although it is unusual for patients with sCJD to have 
raised total protein concentrations and/or WCC, a 
small number of patients with sCJD have had CSF 
total protein concentrations of >1.0 g/L or WCC of 
>10 x 10^6/L .24
Many laboratories are reluctant to analyse CSF 
samples from patients with suspected CJD due to the 
perceived transmission risk. The current guidelines 
from the UK Department of Health and Advisory 
Committee on Dangerous Pathogens’ Transmissible 
Spongiform Encephalopathy subgroup advise that CSF 
is a low-risk specimen and that no additional precau-
tionary measures are required for biochemical and 
cytological analysis (part 3 and annex K).25
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Table 1 Reported sensitivities and specificities of RT-QuIC in sCJD, using different rPrP substrates.1
RT-QuIC rPrP Patient group (n)
Sensitivity 
(%)
Sensitivity in 
different PRNP 
codon 129 
genotypes (%) Controls (n)
Specificity 
(%) Reference
First generation Full-length 
human
Neuropathologically 
confirmed sCJD (34)
85 MM (86); MV 
(100); VV (75)
Neurodegenerative 
disease controls 
(165)
100 Atarashi et al6
First generation Full-length 
human
Neuropathologically 
confirmed and probable 
sCJD (81)
77 ND Non-CJD controls 
(100)
100 Park et al10
First generation Full-length 
hamster
Neuropathologically 
confirmed sCJD (123)
89 MM (90); MV 
(88); VV (95)
Non-CJD controls 
(103)
99 McGuire et al8
First generation Full-length 
hamster
Neuropathologically 
confirmed sCJD (15)
Probable sCJD1 (13)
87
 
69
MM (78); MV 
(75); VV (100)
Neurodegenerative 
disease (12) and no 
neurological disorder 
(31) controls
100 Orrú et al15
First generation Full-length 
hamster
Neuropathologically 
confirmed sCJD (36)
Probable sCJD1 (68)
69
 
79
MM (71); MV 
(66); VV (33)
Non-prion disease 
controls (64)
100 Groveman et al 
First generation Full-length 
hamster
Neuropathologically 
confirmed sCJD (179)
Probable sCJD1 (97)
83
 
79
MM (84); MV 
(72); VV (80)
Non-CJD controls 
(915)
99 Lattanzio et al12
First generation Full-length 
hamster
Neuropathologically 
confirmed sCJD (24)
Probable sCJD1 (26)
79
65
ND No controls NA Bongianni et al13
Second 
generation
Truncated 
hamster
Neuropathologically 
confirmed sCJD (48)
96 MM (95); MV 
(100); VV (100)
Neurodegenerative 
disease controls (30)
 
Controls no 
neurological disorder 
(9)
100 Orrú et al15
Second 
generation
Truncated 
hamster
Neuropathologically 
confirmed sCJD (36)
Probable sCJD1 (68)
94
 
97
MM (94); MV 
(66); VV (66)
Non-prion disease 
controls (64)
100 Groveman et al 11
Second 
generation
Truncated 
hamster
Neuropathologically 
confirmed sCJD (10)
Probable sCJD1 (12)
70
 
100
ND Non-CJD controls 
(17)
100 Bongianni et al13
Second 
generation
Truncated 
hamster
Neuropathologically 
confirmed sCJD (116)
Probable sCJD1 (73)
92
 
95
MM (92); MV 
(92); VV (98)
Non-CJD controls 
(100)
100 Franceschini et 
al17
Second 
generation
Truncated 
hamster
Neuropathologically 
confirmed sCJD (174)
93 MM (94); MV 
(94); VV (94)
Non-CJD controls 
(82)
98 Foutz et al16
Diagnosis of probable sCJD made according to the WHO criteria.31
MM, methionine; MV, methionine and valine; NA, not available; ND, not done; RT-QuIC, real-time quaking-induced conversion; VV, valine; rPRP, 
recombinant prior protein; sCJD, sporadic Creutzfeldt-Jakob disease.
False-positive csF rt-quIc results
In contrast to other CSF biomarkers such as 14-3-3 and 
tau protein, RT-QuIC has a high degree of specificity 
in the investigation of sCJD. There are currently eight 
cases reported in the literature with a ‘false’ positive CSF 
RT-QuIC results (table 3).8 12 16 22 26 Only three of these 
cases underwent postmortem examination and one had 
dementia with Lewy bodies confirmed; however, subse-
quent western blotting of the brain tissue found small 
amounts of abnormal PrPSc. This raises the possibility 
that this patient also had subclinical sCJD. The diagnoses 
in the remaining two cases were frontotemporal lobar 
degeneration-TAR DNA-binding protein 43 kDa with 
motor neurone disease and steroid-responsive enceph-
alopathy presenting with convulsion. In both of these 
cases, the CSF RT-QuIC traces were reported as slowly 
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Key Points
 ► Cerebrospinal fluid real-time quaking-induced 
conversion (CSF RT-QuIC) is a highly sensitive and 
specific test for sporadic Creutzfeldt-Jakob disease 
(sCJD).
 ► It is not affected by age at onset of disease or PRNP 
codon 129; however, it may be less sensitive in the 
rarer forms of sCJD such as MM2 (methionine) with 
cortical changes and VV1 (valine).
 ► Of those patients who are negative for CSF RT-
QuIC, 90% have an alternative positive diagnostic 
investigation, such as CSF 14-3-3, the presence of 
cortical ribboning and/or basal ganglia changes on 
MRI or triphasic waves on electroencephalogram.
 ► The interpretation of CSF RT-QuIC is hampered by the 
presence of elevated red cell counts (>1250 x 10^6/L), 
white cell counts (>10 x 10^6/L ) and raised total 
protein concentrations (>1 g/L).
 ► CSF RT-QuIC may be less sensitive in the rarer sCJD 
subtypes such as sCJD-MM2 associated with cortical 
changes and sCJD-VV1.
Table 2 Sensitivity of CSF RT-QuIC in different sCJD subtypes
sCJD subtype
Sensitivity (%)
First-generation 
RT-QuIC12 (total 
number cases 
investigated)
Sensitivity (%)
Second-generation 
RT-QuIC16 (total 
number cases 
investigated)
MM1/MV1 89 (111) 96 (119)
MV2 81 (26) 89 (9)
MM2 42 (10) 78 (9)
VV1 100 (1) 75 (8)
VV2 78 (27) 100 (27)
CSF, cerebrospinal fluid; MM, methionine; MV, methionine and valine; 
RT-QuIC, real-time quaking-induced conversion; sCJD, sporadic 
Creutzfeldt-Jakob disease;VV, valine.
Table 3 Clinical information and neuropathological and diagnostic investigations in eight patients with ’false’ positive CSF RT-QuIC results
Case
CSF RT-QuIC 
result Final diagnosis
Disease duration 
(months)
Immunohistochemistry/
western blotting for PrPSc
CSF 14-
3-3
Diffusion-
weighted MRI
1 Positive Vascular dementia 17 Not performed Positive Vascular changes
2 Positive Suspected frontotemporal 
dementia (lost to follow-up)
17 Not performed Negative Negative
3 Positive Rapid progressive dementia 
with paraneoplastic syndrome
4 Not performed Positive NA
4 Positive Diffuse dementia with Lewy 
bodies
NA Negative/Positive Not done NA
5 Positive Alzheimer’s disease NA Not performed Negative NA
6 Positive Encephalopathy presenting with 
convulsion
NA Not performed Positive Cortical 
hyperintensity
7 Positive (slowly 
amplified)
FTLD-TDP43 with motor 
neurone disease
NA Negative/Negative Negative NAD
8 Positive (slowly 
and slightly 
amplified)
Steroid-responsive 
encephalopathy presenting with 
convulsion
3 Negative/Negative Positive Cortical 
hyperintensity 
during acute phase
CSF, cerebrospinal fluid; FTLD-TDP43, frontotemporal lobar degeneration-TAR DNA-binding protein 43 kDa;NA, not available;NAD, no abnormality 
detected; PrP, prion protein; RT-QuIC, real-time quaking-induced conversion.
and slightly amplifying. A diagnosis of sCJD could not be 
ruled out in the remaining six cases.
csF rt-quIc In other prIon dIseAses
There is less information available on the utility of CSF 
RT-QuIC in genetic forms of prion disease. However 
there are increasing data to suggest that CSF RT-QuIC 
has a high degree of sensitivity in the commoner muta-
tions in the PRNP gene such as E200K (82%–100%) 
or the insert mutations (100%).12 27 There are fewer 
data for the rarer mutations. CSF RT-QuIC is not posi-
tive in variant CJD, although an alternative form of 
protein aggregation assay known as protein multipli-
cation cyclic amplification has reportedly been able to 
detect PrPSc in CSF in variant CJD but not in sCJD; 
this suggests that a combination of these two tech-
niques may potentially discriminate between these two 
forms of CJD in life.28 29 In our experience, approxi-
mately 67% of patients with iatrogenic CJD secondary 
to cadaveric growth hormone administration are posi-
tive for CSF RT-QuIC.
rt-quIc using other biological fluids and tissues
As yet, there is no reliable blood RT-QuIC assay for 
prion diseases for reasons that are outlined above. 
RT-QuIC analysis of olfactory neuroepithelium nasal 
brushings has been shown to have a comparable spec-
ificity and improved sensitivity when compared with 
CSF analysis.9 13 However, it is not routine to collect 
such samples and the technique may require specialist 
expertise, which limits its usefulness in a clinical 
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setting. A recent report showed that skin samples 
from patients with sCJD and variant CJD are posi-
tive by RT-QuIC analysis, but this has not yet been 
replicated.30 The skin sample preparation is complex 
involving homogenisation, phosphotungstate precip-
itation and ultracentrifugation, and this reduces its 
practicality as a routine diagnostic test.
update from the ncJdrsu
Using the first-generation technique8 the National 
CJD Research & Surveillance Unit (NCJDRSU) has 
analysed over 1600 CSF samples, including 616 sCJD 
cases, and our current sensitivity for sCJD is 92% 
and our specificity is 100%. Of those 616 sCJD cases 
investigated, 52 were negative for CSF RT-QuIC, and 
of these 32 were positive for CSF 14-3-3 and an addi-
tional 15 cases had other supportive investigations, 
such as cortical ribboning and/or high signal in the 
basal ganglia on MRI or triphasic waves seen on EEG. 
Only five cases were negative for all clinical diagnostic 
tests and these cases were diagnosed at postmortem.
We are currently undertaking parallel study 
comparing our current first-generation CSF RT-QuIC 
assay with the second-generation CSF RT-QuIC assay 
with the view to moving to the second-generation 
system provided the same degree of sensitivity and 
specificity can be guaranteed, thereby reducing the 
turnaround time by 50%.
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